Antithrombotic therapy following transcatheter aortic valve implantation: what challenge do we face?

Expert Rev Cardiovasc Ther. 2016;14(3):381-9. doi: 10.1586/14779072.2016.1124760. Epub 2016 Jan 20.


The issue of stroke and bleeding events following transcatheter aortic valve implantation (TAVI) and its relation with antithrombotic regimens before, during and after the procedure is increasingly recognized as an important issue. While dedicated trials are ongoing, there is no clear evidence at present on the best antithrombotic regimen in the context of TAVI. In this article, we will go through the mechanisms involved in embolic and bleeding complications of TAVI, and we will discuss the key aspects of antithrombotic treatment in patients undergoing TAVI.

Keywords: TAVI; anticoagulant therapy; antiplatelet therapy; aspirin; bivalirudin; bleeding; clopidogrel.

Publication types

  • Review

MeSH terms

  • Fibrinolytic Agents / therapeutic use*
  • Hemorrhage / etiology
  • Humans
  • Stroke / etiology
  • Transcatheter Aortic Valve Replacement / adverse effects
  • Transcatheter Aortic Valve Replacement / methods*


  • Fibrinolytic Agents